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The ClinicalTrials.gov Results Database
To the Editor: Zarin et al. (March 3 issue)1 pro-
vide an update on ClinicalTrials.gov, currently the 
only publicly available database reporting trial 
results; it should be used in systematic reviews 
and meta-analyses. Of the researchers who wrote 
more than 12,000 such reviews and meta-analy-
ses published and indexed in PubMed between 
2009 and 2010, less than 2% reported using 
ClinicalTrials.gov to search for unpublished data.2 
The scarce utilization suggests the scientific com-
munity is not sufficiently aware of ClinicalTrials 
.gov or else struggles with implementation of this 
key resource for synthesis of research.
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To the Editor: We report an experience with 
ClinicalTrials.gov and our international random-
ized, controlled trial CHIPS (Control of Hyper-
tension In Pregnancy Study). CHIPS is funded by 
the Canadian Institutes of Health Research, which 
mandates registration and assignment of an Inter-
national Standard Randomised Controlled Trial 
Number (ISRCTN) (no. 71416914). However, one 
of our active international sites discovered that 
CHIPS had been registered on ClinicalTrials.gov 
by another interested (but not active) site. The 
ClinicalTrials.gov entry contained many factual 
errors. Although we have now overridden this 
submission, is there a mechanism to prevent du-
plicate and inaccurate registration?
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To the Editor: There are considerable disincen-
tives to the reporting requirement in ClinicalTrials 
.gov. Three examples include the fact that all data 
entry has to be performed manually rather than 
being uploaded with the use of commonly used 
software programs and formats such as Micro-
soft Word, Adobe Portable Document Format 
(PDF), Microsoft Excel, or SAS statistical software. 
Another problem is that the different measures 
of “dispersion” (e.g., standard error, standard de-
viation, 95% confidence interval, and interquar-
tile range) within studies add complexity to data 
entry in various tables. Finally, the space allotted 
to specific sections (e.g., statistical analysis) is 
insufficient.
Michael Camilleri, M.D.
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To the Editor: ClinicalTrials.gov has important 
quality-control measures to prevent information 
in registered records from being omitted, incom-
plete, incorrect, or uninformative. Unfortunately, 
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the quality of registered trial data across regis-
tries remains a problem. Using one of the criteria 
proposed by Zarin et al., we identified “internal 
inconsistency” as a problem in about 9% of rec-
ords in the World Health Organization (WHO) 
International Clinical Trials Registry Platform 
(ICTRP) search portal.1 In the records for these 
trials, multiple descriptors that are not compati-
ble — such as “single-group” and “controlled or 
randomized”; “open-label” and “blinded”; and 
“double-blinded without subject or investigator 
blinding” — were used.
The ICTRP has now established International 
Standards for Clinical Trial Registries, which set 
a minimum requirement for quality-control pro-
cesses performed and data recording practices 
used by individual registries. The intention is to 
implement these minimum standards and mon-
itor compliance by registries in the WHO Regis-
try Network to ultimately achieve the recording 
of more complete and meaningful clinical-trial 
information.
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The Authors Reply: We agree with Wyler von 
Ballmoos and Oliveira that ClinicalTrials.gov is 
an important resource for systematic reviewers 
as well as for anybody else (e.g., members of in-
stitutional review boards) who seeks the com-
plete evidence base on a given topic. Since the 
results of many clinical trials remain unpub-
lished,1 even years after completion, it is clear 
that a literature search alone will not result in a 
complete picture of the evidence.
Magee and Menzies raise the issue of dupli-
cate and inaccurate registrations. We previously 
addressed the importance of preventing duplicate 
registrations and ensuring the accuracy of reg-
istrations.2 To prevent unintended duplicate reg-
istrations, the sponsor, study sites, and all relevant 
parties must identify the one person who will be 
responsible for trial-registration and related re-
porting activities; that person would be designat-
ed as the responsible party in ClinicalTrials.gov. 
Individual study-site investigators should not reg-
ister their study unless they serve as the respon-
sible party for the overall trial. If a study must 
be submitted to multiple registries (e.g., to com-
ply with regional policies), we ask that the NCT 
number and other registry identifiers be listed in 
all registrations to allow for the identification of 
(intentional) duplicate records. Regarding inaccu-
racies, although our staff manually reviews each 
record, certain factual errors cannot be detected 
without access to the study data. It is essential 
that the responsible party has the necessary ex-
pertise to submit accurate and informative data.
Camilleri notes that ClinicalTrials.gov does 
not allow for the uploading of data in formats 
used by popular software platforms. However, 
ClinicalTrials.gov does support the uploading of 
data in the Extensible Markup Language (XML) 
format, a standard method of encoding informa-
tion in an unambiguous machine-readable struc-
ture — unlike the data-file formats mentioned by 
Camilleri. Without the structured numeric entries 
afforded by the XML format, it would not be 
possible for the ClinicalTrials.gov system to per-
form automated validation of entries or to provide 
consistent displays of data.
We agree with Viergever and Ghersi that reg-
istries must implement quality-control measures. 
However, the quality of entries will always be 
dependent on the diligence and integrity of the 
person entering the data.
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